Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, coagulation factor VIII/Von Willebrand factor (Voncento®) cannot be endorsed for use within NHS Wales for the treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with Von Willebrand disease, when desmopressin treatment alone is ineffective or contraindicated and prophylaxis and treatment of bleeding in patients with haemophilia A (congenital factor VIII deficiency). |
||
|
||
Medicine details |
||
| Medicine name | coagulation factor VIII/von Willebrand factor (Voncento®) | |
| Formulation | 250 IU/600 IU, 500 IU/1200 IU and 1000 IU/2400 IU powder and solvent for solution for injection/infusion | |
| Reference number | 2226 | |
| Indication | Treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with Von Willebrand disease, when desmopressin treatment alone is ineffective or contraindicated and prophylaxis and treatment of bleeding in patients with haemophilia A (congenital factor VIII deficiency) |
|
| Company | CSL Behring UK Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 06/12/2013 | |